Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
5,420.00
-40.00 (-0.73%)
Last updated: Mar 28, 2025
Kwang Dong Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Other Revenue | - | - | - | -0 | - | Upgrade
|
Revenue | 1,640,719 | 1,514,454 | 1,431,545 | 1,338,182 | 1,243,770 | Upgrade
|
Revenue Growth (YoY) | 8.34% | 5.79% | 6.98% | 7.59% | 0.45% | Upgrade
|
Cost of Revenue | 1,343,737 | 1,216,563 | 1,151,550 | 1,065,870 | 987,672 | Upgrade
|
Gross Profit | 296,982 | 297,891 | 279,995 | 272,312 | 256,098 | Upgrade
|
Selling, General & Admin | 246,225 | 233,331 | 225,167 | 213,458 | 196,462 | Upgrade
|
Research & Development | 10,128 | 15,275 | 9,678 | 8,322 | 5,957 | Upgrade
|
Other Operating Expenses | 2,059 | 1,989 | 1,391 | 1,589 | 2,857 | Upgrade
|
Operating Expenses | 266,885 | 255,821 | 241,751 | 227,376 | 209,507 | Upgrade
|
Operating Income | 30,097 | 42,070 | 38,244 | 44,936 | 46,591 | Upgrade
|
Interest Expense | -10,274 | -6,904 | -3,735 | -2,544 | -2,539 | Upgrade
|
Interest & Investment Income | 6,319 | 5,399 | 2,844 | 2,415 | 2,850 | Upgrade
|
Earnings From Equity Investments | 767.76 | -429.82 | -435.51 | -112.22 | -62.65 | Upgrade
|
Currency Exchange Gain (Loss) | 3,159 | -384.81 | 6.49 | 693.27 | -800.07 | Upgrade
|
Other Non Operating Income (Expenses) | -1,169 | -179.12 | 1,132 | -865.71 | 932.94 | Upgrade
|
EBT Excluding Unusual Items | 28,900 | 39,571 | 38,056 | 44,522 | 46,972 | Upgrade
|
Gain (Loss) on Sale of Investments | 25,399 | 9,412 | -1,932 | -10,232 | 17,536 | Upgrade
|
Gain (Loss) on Sale of Assets | 3,026 | -1,964 | 166.52 | 38.87 | 1,178 | Upgrade
|
Asset Writedown | - | - | - | - | -2,735 | Upgrade
|
Pretax Income | 57,325 | 49,019 | 36,291 | 34,329 | 62,951 | Upgrade
|
Income Tax Expense | 15,480 | 9,648 | 9,590 | 8,788 | 17,349 | Upgrade
|
Earnings From Continuing Operations | 41,845 | 39,372 | 26,701 | 25,541 | 45,602 | Upgrade
|
Minority Interest in Earnings | -1,364 | -2,406 | -2,527 | -1,522 | -232.19 | Upgrade
|
Net Income | 40,481 | 36,966 | 24,174 | 24,019 | 45,370 | Upgrade
|
Net Income to Common | 40,481 | 36,966 | 24,174 | 24,019 | 45,370 | Upgrade
|
Net Income Growth | 9.51% | 52.91% | 0.65% | -47.06% | 96.76% | Upgrade
|
Shares Outstanding (Basic) | 40 | 40 | 41 | 41 | 41 | Upgrade
|
Shares Outstanding (Diluted) | 40 | 40 | 41 | 41 | 41 | Upgrade
|
Shares Change (YoY) | -1.10% | -1.44% | -0.11% | 1.48% | 2.24% | Upgrade
|
EPS (Basic) | 1011.00 | 913.00 | 588.45 | 584.68 | 1119.49 | Upgrade
|
EPS (Diluted) | 1011.00 | 913.00 | 588.00 | 584.33 | 1119.00 | Upgrade
|
EPS Growth | 10.73% | 55.27% | 0.63% | -47.78% | 92.36% | Upgrade
|
Free Cash Flow | -87,883 | -46,515 | 37,439 | 31,145 | 17,566 | Upgrade
|
Free Cash Flow Per Share | -2194.85 | -1148.87 | 911.36 | 757.27 | 433.44 | Upgrade
|
Dividend Per Share | - | - | 100.000 | 100.000 | 100.000 | Upgrade
|
Dividend Growth | - | - | - | - | 25.00% | Upgrade
|
Gross Margin | 18.10% | 19.67% | 19.56% | 20.35% | 20.59% | Upgrade
|
Operating Margin | 1.83% | 2.78% | 2.67% | 3.36% | 3.75% | Upgrade
|
Profit Margin | 2.47% | 2.44% | 1.69% | 1.80% | 3.65% | Upgrade
|
Free Cash Flow Margin | -5.36% | -3.07% | 2.61% | 2.33% | 1.41% | Upgrade
|
EBITDA | 44,629 | 54,974 | 52,262 | 59,045 | 66,299 | Upgrade
|
EBITDA Margin | 2.72% | 3.63% | 3.65% | 4.41% | 5.33% | Upgrade
|
D&A For EBITDA | 14,532 | 12,904 | 14,017 | 14,110 | 19,709 | Upgrade
|
EBIT | 30,097 | 42,070 | 38,244 | 44,936 | 46,591 | Upgrade
|
EBIT Margin | 1.83% | 2.78% | 2.67% | 3.36% | 3.75% | Upgrade
|
Effective Tax Rate | 27.00% | 19.68% | 26.43% | 25.60% | 27.56% | Upgrade
|
Advertising Expenses | 45,513 | 46,186 | 42,214 | 40,464 | 37,872 | Upgrade
|
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.